← Eichor
Condition: Stage Iv Breast Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Stage Iv Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac
Phase 3 · 590 location(s) · SWOG Cancer Research Network · NCT03418961Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 · 40 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06625775A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
Phase 1/Phase 2 · 22 location(s) · Forward Pharmaceuticals Co., Ltd. · NCT06064812Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT07476170Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
Phase 2 · 1 location(s) · The Methodist Hospital Research Institute · NCT05305924HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan
Phase 2 · 10 location(s) · SOLTI Breast Cancer Research Group · NCT06236269Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastat
Phase 1/Phase 2 · 2 location(s) · Shandong Suncadia Medicine Co., Ltd. · NCT06167694RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07065435Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Br
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT06860815A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurr
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07520760High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metast
Phase 2 · 1 location(s) · Emory University · NCT06492759A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06246968Metastases Directed Therapy for Oligometastatic Breast Cancer
NA · 1 location(s) · National Cancer Institute, Egypt · NCT06144346A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06493864Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer
Phase 2 · 1 location(s) · Yeon Hee Park · NCT06616987Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and C
Phase 1/Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT06298084The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Phase 3 · 73 location(s) · American Society of Clinical Oncology · NCT06377852Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Canc
Phase 3 · 31 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT07008976Promoting Active Living Among People With Metastatic Breast Cancer
NA · 1 location(s) · University of Oklahoma · NCT07238023Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
Phase 2 · 1 location(s) · Mayo Clinic · NCT06635980Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Canc
Phase 2 · 1 location(s) · RemeGen Co., Ltd. · NCT06642545A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT04683679Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
Phase 1 · 1 location(s) · Fudan University · NCT06331169DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients
Phase N/A · 1 location(s) · Mayo Clinic · NCT06388122Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer:
Phase N/A · 1 location(s) · Fundación Pública Andaluza para la Investigación Biomédica A · NCT07582887Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer
Phase 2 · 2 location(s) · Fudan University · NCT07471776Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment
NA · 51 location(s) · UNICANCER · NCT06505018Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Br
Phase 1/Phase 2 · 3 location(s) · Washington University School of Medicine · NCT06374459Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
Phase 2 · 9 location(s) · Institut Curie · NCT07193394Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors,
Phase N/A · 1 location(s) · Hunan Cancer Hospital · NCT07073755
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.